Blueprint Medicines Corp

Blueprint Medicines is an oncology firm that develops kinase inhibitors for genomically defined cancer subsets. Read more

Jeffrey W. Albers's photo - President & CEO of Blueprint Medicines Corp

President & CEO

Jeffrey W. Albers

CEO Approval Rating

100/100

Founded:

2011

Status:

PublicIndependent CompanyNASDAQBPMC

Annual Revenue
Employees
Sector

- -

BLUEPRINT MEDICINES CORP TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Tarveda is Blueprint Medicines Corp's #1 rival. Tarveda is a Private company that was founded in Watertown, Massachusetts in 2011. Tarveda competes in the Biotechnology field. Tarveda has 172 fewer employees vs. Blueprint Medicines Corp.

OncoResponse is perceived as one of Blueprint Medicines Corp's biggest rivals. OncoResponse was founded in 2015, and is headquartered in Seattle, Washington. OncoResponse is in the Biotechnology field. OncoResponse generates $805.1M less revenue vs. Blueprint Medicines Corp.

Selecta Biosciences is a top competitor of Blueprint Medicines Corp. Selecta Biosciences is a Public company that was founded in 2007 in Watertown, Massachusetts. Selecta Biosciences competes in the Biotechnology industry. Compared to Blueprint Medicines Corp, Selecta Biosciences has 174 fewer employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is NexImmune a competitor of Blueprint Medicines Corp?

Blueprint Medicines Corp Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$809.1M

Blueprint Medicines Corp's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 52.7M. Over the last four quarters, Blueprint Medicines Corp's revenue has grown by 158.6%. Specifically, in Q1 2021's revenue was $21.6M; in Q4 2020, it was $34.1M; in Q3 2020, it was $745.1M; in Q2 2020, Blueprint Medicines Corp's revenue was $8.3M.

Blueprint Medicines Corp Acquisitions

No recent acquisitions found related to Blueprint Medicines Corp

Blueprint Medicines Corp Funding History

Since Blueprint Medicines Corp was founded in 2011, it has participated in 4 rounds of funding. In total Blueprint Medicines Corp has raised $259.8M. Blueprint Medicines Corp's last funding round was on Apr 2015 for a total of $146.6M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Apr 2015
$146.6M

Series C
Nov 2014
$50M

Wellington Management

Series B
Jan 2014
$23.2M
Series A
Apr 2011
$40M

Since Blueprint Medicines Corp was founded in 2011, it has participated in 4 rounds of funding. In total Blueprint Medicines Corp has raised $259.8M. Blueprint Medicines Corp's last funding round was on Apr 2015 for a total of $146.6M

Blueprint Medicines Corp Investments

No recent investments found related to Blueprint Medicines Corp

Blueprint Medicines Corp News

April 7, 2021BioSpace

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 07, 2021

Blueprint Medicines Corporation announced that, effective on April 1, 2021, the Compensation Committe... See more »
March 5, 2021MarketScreener

Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

(marketscreener.com) CAMBRIDGE, Mass., March 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation ... See more »
February 17, 2021NewsOk

4Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp.Read more on NewsOK.com... See more »
February 17, 2021The Washington Times

4Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Wednesday reported a loss of $85.7 millio... See more »
February 5, 2021Markets Insider

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a prec... See more »

Blueprint Medicines Corp Press Releases

April 5, 2021PR Newswire

Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021

CAMBRIDGE, Mass., April 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today... See more »
March 10, 2021PR Newswire

Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021

CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today... See more »
December 7, 2020PR Newswire

Blueprint Medicines Data Presented at 62nd ASH Annual Meeting and Exposition Highlight Broad Commitment to Advance Patient Care in Systemic Mastocytosis

CAMBRIDGE, Mass., Dec. 7, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a prec... See more »
November 23, 2020PRWeb

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO (pralsetinib)

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturi... See more »
November 23, 2020PR Newswire

Blueprint Medicines To Present Broad Range of Data Reinforcing Commitment to Advance Patient Care in Systemic Mastocytosis at 62nd ASH Annual Meeting and Exposition

CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a pre... See more »
September 9, 2020PR Newswire

Blueprint Medicines to Present at 18th Annual Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a prec... See more »
July 2, 2020PR Newswire

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 2, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a prec... See more »

Social Media

Blueprint Medicines Corp Headquarters

45 Sidney Street

Cambridge, Massachusetts02139

617-374-7580

Driving Directions »

Trending Companies

Blueprint Medicines Corp Summary

ABOUT

Overview

Blueprint Medicines is an oncology firm that develops kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp was founded in 2011. Blueprint Medicines Corp's headquarters is located in Cambridge, Massachusetts, USA 02139. It...

CEO

Blueprint Medicines Corp's President & CEO, Jeffrey W. Albers, currently has an approval rating of 100%. Blueprint Medicines Corp's primary competitors are Tarveda, OncoResponse & Selecta Biosciences.

Frequently Asked Questions about Blueprint Medicines Corp

  1. When was Blueprint Medicines Corp founded?

    Blueprint Medicines Corp was founded in 2011
  2. Who is Blueprint Medicines Corp's CEO?

    Blueprint Medicines Corp's CEO is Jeffrey W. Albers
  3. How much revenue does Blueprint Medicines Corp generate?

    Blueprint Medicines Corp generates $809.1M in revenue
  4. How much funding does Blueprint Medicines Corp have?

    Blueprint Medicines Corp has historically raised $259.8M in funding
  1. Where is Blueprint Medicines Corp's headquarters?

    Blueprint Medicines Corp's headquarters is in Cambridge Massachusetts, USA
  2. How many employees does Blueprint Medicines Corp have?

    Blueprint Medicines Corp has 217 employees
  3. Who are Blueprint Medicines Corp's competitors?

    Blueprint Medicines Corp's top competitors are Tarveda, OncoResponse, Selecta Biosciences